Hepion Pharmaceuticals Announces Advancement to Fourth Dose Level in Ongoing Multiple Ascending Dose Clinical Study of CRV431

Stock Information for Hepion Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.